HUMA 8-K 2026-11-10

Humacyte, Inc. (HUMA) 8-K dated 2026-11-10 — accession 0001193125-26-454402.

Humacyte, Inc. (HUMA) common stock.

HUMAW: # Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported HUMA revenue for 2025-12-31 was $2.0M. Net income was -$40.8M. HUMA currently screens at market cap $126.5M.

Not investment advice. The HUMA SEC hub lists recent forms. The stock page is the research view.